Side Effects of Allergy Shots in Adults: The Comorbidity Guide

Research suggests allergy shots are safe for adults aged 60-75 when properly screened. A 2016 study by Bozek (Allergy Asthma Proc) found comparable efficacy and safety in patients aged 60-75 versus younger adults, with no increased systemic reaction rate. The key difference is that older adults are more likely to have comorbidities — cardiovascular disease, COPD, or polypharmacy — that require more thorough pre-injection screening. Uncontrolled asthma remains the dominant risk factor for serious reactions regardless of age. Allergists will assess FEV1, review all medications including beta-blockers, and check blood pressure before each injection for older patients.

Beta-blocker use is listed as a relative contraindication for allergy shots in the AAAAI/ACAAI Practice Parameter, but the guidance has evolved. A 2021 study by Sturm (Allergy, n=1,425) found no increased adverse event rates in patients on beta-blockers during venom immunotherapy, challenging the historical absolute contraindication. The concern is mechanistic: beta-blockers impair the body's response to epinephrine, the first-line treatment for anaphylaxis, meaning that if a severe reaction occurs, standard rescue medication may be less effective. Glucagon is the backup rescue option for beta-blocker users. Most allergists will engage in shared decision-making — weighing your cardiac indications against immunotherapy benefits — rather than categorically refusing treatment. Disclose beta-blocker use before your first appointment.

ACE inhibitor use carries a theoretical increased risk during allergy shots. ACE inhibitors prevent the breakdown of bradykinin, a compound that can amplify swelling, low blood pressure, and vasodilation during allergic reactions. A 2009 study by Rueff (JACI) found ACE inhibitors were a predictor of more severe systemic reactions during venom immunotherapy in patients with insect sting allergies. For inhalant SCIT — the shots used for pollen, dust mites, and pet dander — the evidence is less clear, and ACE inhibitors are not listed as a contraindication in current guidelines. However, the 2011 Practice Parameter recommends shared decision-making. Discuss your ACE inhibitor use explicitly with your allergist before starting treatment.

Allergy shots can be highly beneficial for adults with allergic asthma — evidence shows SCIT reduces asthma medication use and improves FEV1 over time. However, uncontrolled asthma significantly increases the risk of severe reactions during treatment. In the Bernstein 2004 fatality survey, 88% of detailed SCIT fatalities occurred in patients with asthma, most of it suboptimally controlled. The 2011 Practice Parameter considers FEV1 below 70% predicted a relative contraindication. Injections should not be given when asthma is actively flaring. Your allergist will measure peak flow before each injection, and may defer treatment on days your asthma is poorly controlled. With well-controlled asthma, the risk-benefit ratio strongly favors treatment.

Allergy shots can be continued during pregnancy if you were already at maintenance dose when you became pregnant, but dose escalation is contraindicated during pregnancy. The 2011 AAAAI/ACAAI Practice Parameter clearly states that immunotherapy can be continued but is usually not initiated during pregnancy. The concern is that systemic reactions during pregnancy could cause uterine contractions or fetal hypoxia. Long-term data are reassuring: a 1978 study by Metzger (n=121 pregnancies) found no excess complications in women continuing SCIT, and a 2022 Swedish nationwide registry study of 743 AIT-exposed pregnancies found no associations with adverse birth outcomes. Discuss your specific situation with both your allergist and OB to determine the safest protocol.

Epinephrine response can be attenuated in older adults and those with cardiovascular disease. Research by Simons (JACI 2010) documents slower heart rate recovery and greater hypertensive overshoot in older patients following epinephrine administration. This does not mean epinephrine should be withheld — it remains the non-negotiable first-line treatment for anaphylaxis. Rather, it means that clinic staff treating older adults may need to monitor cardiac response more carefully after epinephrine and be prepared for follow-on doses. Adults on beta-blockers specifically may need glucagon (1-5 mg IV) as an alternative if epinephrine is insufficient. The 30-minute post-injection observation period is particularly important for adults with cardiovascular comorbidities.

Post-injection fatigue — a common patient complaint on forums and in clinical practice — has not been rigorously quantified by age group in controlled trials. The mechanism involves pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) released during the immune response triggering hypothalamic 'sickness behavior' signaling — the same pathway behind post-vaccination fatigue. Adults may experience this more prominently if they have baseline inflammatory conditions or are doing less well-tolerated build-up doses. Fatigue is typically most noticeable during build-up weeks 4-12 and tends to diminish or disappear during maintenance. Scheduling injections in the afternoon and planning low-exertion activities afterward can help. Fatigue lasting more than 48 hours warrants a call to your allergist.